Physician profile
Gary G Chen
NPI 1902978141
$7,953.80
in general payments reported to CMS, 2019-2025
35 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,551 · 2020: $364 · 2021: $953 · 2022: $905 · 2023: $1,191 · 2024: $1,183 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,146 · Education: $35.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,146.16 |
| Education | $35.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,678.63 | 2019-2025 | Epclusa, Vemlidy |
| Astrazeneca Pharmaceuticals LP | $1,483.35 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $553.73 | 2019-2024 | |
| Glaxosmithkline, LLC. | $539.35 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Janssen Pharmaceuticals, INC | $431.33 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $412.78 | 2021-2023 | Watchman Access System, Opticross |
| Amarin Pharma, INC. | $405.90 | 2019-2023 | |
| Angiodynamics, INC. | $260.48 | 2024 | Angiodynamics, Nanoknife |
| Nestle Healthcare Nutrition INC. | $182.88 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.22 | 2021-2025 | |
| Pfizer INC. | $161.97 | 2019 | |
| Abbott Laboratories | $136.16 | 2022 | |
| Medtronic, INC. | $135.30 | 2022 | |
| Sirtex Medical INC | $134.49 | 2023 | Sir-Spheres Microspheres |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2025 | Jardiance |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $124.92 | 2019 | |
| Microvention, INC. | $117.07 | 2021 | |
| Astellas Pharma US INC | $93.89 | 2019-2022 | |
| Allergan, INC. | $90.54 | 2019-2020 | |
| Intra-Sana Laboratories | $81.94 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Abbvie INC. | $78.30 | 2021 | |
| Aimmune Therapeutics, INC. | $77.93 | 2024-2025 | Zenpep |
| Kowa Pharmaceuticals America, INC. | $62.78 | 2019-2025 | Zoryve |
| Lilly USA, LLC | $52.93 | 2019 | |
| Amgen INC. | $49.40 | 2021-2025 | Repatha, Otezla, Repatha |
| Seqirus USA INC | $46.27 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $42.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.91 | 2019 | |
| Sumitomo Pharma America, INC. | $35.62 | 2023 | Myfembree |
| Corcept Therapeutics | $35.61 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $32.16 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $25.69 | 2019 | |
| Kyowa Kirin, INC. | $18.91 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.59 | 2023 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $14.34 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.